71 results about "Topical uses" patented technology

The invention relates to a product for topical use in the treatment of skin affected by dysbiosis. The product has a pH ranging from 5.5 to 6.5 and essentially comprises water, glycerin and at least one crosslinked polyacrylate. This product can be used as a prerequisite for the transplantation of biological material favorable to the development of a healthy cutaneous bacterial flora.

Provided herein are compositions for topical use comprising an imidazole or a salt thereof, and domiphen bromide as active ingredients for use in treating or preventing a fungal infection, wherein said imidazole is chosen from ketoconazole and clotrimazole as active ingredients for use in treating or preventing a fungal infection.

A biocompatible adhesive suitable for both internal and topical use. The adhesive is a tissue-adhesive hydrogel formed from an oxidized carboxymethylcellulose (oCMC) with aldehyde functional groups and a methacrylated methylcellulose (mMC).

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

To search for a new active ingredient that is effective in improvement, treatment, and prevention of periodontal disease, and to provide a periodontal disease preventive or therapeutic agent including the new active ingredient.SOLUTION: A periodontal disease preventive or therapeutic agent containing dextromethorphan and / or a salt thereof, an internal or external periodontal disease preventive or therapeutic medicine, and an oral composition for preventing or treating periodontal disease such as a patch, a liniment, a film, a dentifrice, a mouthwash, or a spray, are provided. As the salt of dextromethorphan, dextromethorphan hydrobromide is preferred.SELECTED DRAWING: Figure 2

The present disclosure belongs to the field of pharmaceutical formulations and particularly relates to a composition with a synergistic therapeutic effect on acne lesions and a preparation method therefor and use thereof. The composition provided by the present disclosure comprises active ingredients adapalene and dapsone, which exhibit a synergistic therapeutic effect on inflammatory acne lesions when used in combination. Compared with corresponding single drugs, the composition can significantly reduce the number of inflammatory lesions; meanwhile, relative to the topical use of adapalene alone, the composition of the present disclosure can mitigate skin irritation reactions caused by adapalene and exhibits good safety.

The object of the present invention is Udonitrectag (or Negermin or MTS. IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical use for use in the treatment of dermatological diseases. i.e. of the skin and mucous membranes.

The present invention provides a new silicone gel composition suitable for preparing anti-herpes virus preparations of natural origin.The new composition has the ability to penetrate into the target epidermal side of the skin.The new composition has the ability to be retained on the target epidermal side of the skin for a certain period of time.The present invention also relates to the external use of the silicone gel composition for the treatment of herpes virus in a posology regime.

The present invention relates to a composition and method for solubilizing eggshell membrane at convenient rates. The present invention also relates to organoleptically acceptable products obtained therein, and to their oral or topical application to improve a disease or condition in a subject.

A method for reducing the amount of sebum produced by human skin and / or by the scalp, for preventing, reducing, slowing down, stopping, and / or attenuating the appearance of unsightly, uncomfortable, and / or unpleasant manifestations of the skin and / or scalp in humans due to the secretion of sebum includes topically applying an extract of the alga Halopteris scoparia. Cosmetic or pharmaceutical compositions, in particular dermatological compositions, for topical use, containing an extract of the alga Halopteris scoparia, are also described.

Pharmaceutical compositions for topical use containing diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing treatments requiring the administration of high and accurate dosages to be carried out.

Self-emulsifying formulation for topical, and typically skin use, comprising at least one highly lipophilic active component, a lipophilic portion, an amphiphilic portion, and a skin penetration-promoting portion derived from essential oils.

To provide a topical skin composition that has moderate viscosity while exhibiting excellent stability over time. [Solution] A composition for topical use on the skin, comprising the following components (A) to (F): (A) a polyglycerin fatty acid ester in which R in the fatty acid-derived group R-COO- is an alkyl group having 13 to 23 carbon atoms or an alkenyl group having 13 to 23 carbon atoms; (B) a polyhydric alcohol of trivalent or higher; (C) a polyhydric alcohol of divalent value; (D) an oily component that is liquid at 25°C; (E) a compound represented by formula (I), its salts and mixtures thereof; and (F) a nonionic surfactant other than component (A) and component (E) with an HLB of 4.5 to 12.0, and substantially free of water.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

The problem that this invention aims to solve is the development of a composition intended to protect the skin from ultraviolet rays and that does not have the drawbacks of the prior art. [Solution] The present invention relates to a topical composition that generates a photonic barrier from ultraviolet to visible light, comprising metal-doped crystalline bismuth oxide colloid Bi2O3.

The present invention relates to a gel or cream formulation for topical use, the formulation comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts, where, based on 100 g of the gel or cream formulation, the content of the beta-D-mannuronic acid or alpha-L-guluronic acid or the mixture of beta-D-mannuronic acid and alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha- the total amount of beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts is from 0.5 g to 40 g, said formulation further comprising caffeic acid. Furthermore, the present invention relates to a gel or cream formulation for topical use in a method of treating inflammation and / or any inflammatory response and / or pain, as well as a method of preparing the gel or cream formulation.

The present invention relates to a topical composition creating a photonic barrier from ultraviolet radiation to visible radiation, comprising bismuth oxide colloids Bi2O3 in crystalline form doped with a metal.

The invention relates to a cosmetic composition in the form of an oil-in-water emulsion free of petrolatum and paraffin. This composition comprises water, at least one polyol, 45 to 70% by weight of oily emollient(s), 4 to 15% by weight of waxy consistency factor(s), and at least one emulsifying agent chosen from sucrose and fatty acid esters. This composition proves to be particularly effective for the repair of damaged skin, when applied topically.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.

The invention provides an application of cajanin in preparation of a medicine for treating psoriasis and acne, and belongs to the technical field of traditional Chinese medicines. The invention finds that the longistyline can significantly inhibit proliferation of keratinocytes and secretion of inflammatory factors IL-6 and IL-8 in vitro, significantly inhibit psoriasis skin lesion, significantly reduce psoriasis injury area and severity index score, and significantly reduce epidermis thickness and Ki67 expression in psoriasis skin tissue; in addition, the longistyline can also significantly inhibit the formation of acnes, and can reduce the mRNA expression of acne-related inflammatory factors IL-6, IL-1alpha, IL-1beta, TNF-alpha and IL-23 in skin tissues. The cajanin is used as an effective component, the psoriasis and the acne can be effectively treated in an external application mode, and a new thought is provided for treatment of the psoriasis and the acne.

The present invention discloses the preparation and therapeutic properties of a gel consisting of the active ingredients diclofenac sodium and lysine clonixinate, which are combined for the first time for the topical treatment of pain in musculoskeletal inflammatory processes.

The present invention relates to a topical composition creating a photonic barrier from ultraviolet radiation to visible radiation, comprising bismuth oxide colloids Bi2O3 in crystalline form doped with a metal.

The present invention relates to fast dissolving powder combinations or compositions of high molecular weight hyaluronic acid (HMW-HA) and to processes for preparing HMW-HA water-based fluid compositions comprising them such as a drinkable composition, e.g., a ready to drink (RTD) beverage or another water-based fluid product for oral use containing HMW-HA, or water-based HMW-HA spray product for topical use. The drinkable HMW-HA water-based fluid compositions, for example a RTD beverage of HMW-HA, obtained using the fast-dissolving solid combinations or compositions of the invention are useful for, but not limited to, joint health, skin care, anti-aging. The fast-dissolving solid combinations or compositions of high molecular weight hyaluronic acid (HMW-HA) of the present invention can also be advantageously used for the preparation of a water-based HMW-HA spray product (e.g., a mouth spray, a topical spray for the skin or joints, a lung spray).

The present invention provides compositions of Dodeca-2,4,6,8,10-pentaenoic acid (DDPA) prepared as a composition emulsion for topical use and methods for improving animal skin health. The compositions are useful for treating an inflammatory skin condition by the topical application of an emulsion as an ointment, a cream, a foam, or a gel.

Disclosed is a method for improving the sensorial properties of an oil-in-water type emulsion for topical application, including, for 100% of its mass, 5% to 30% by weight of glycerol, characterised in that the oil-in-water type emulsion for topical application includes an effective quantity of a mixture of saturated cyclic or acyclic, linear or branched hydrocarbons, of which at least 95% by weight have between fifteen and nineteen carbon atoms. Also disclosed is a new oil-in-water type emulsion for topical use, including the mixture, and to the use of same in cosmetics.

The present invention relates to compositions comprising an IRAK4 inhibitor useful for treating dermatological disorders or conditions characterized by inflammation. The present invention also relates to methods for treating dermatological disorders or conditions.

The present invention provides compositions of Dodeca-2,4,6,8,10-pentaenoic acid (DDPA) prepared as a composition emulsion for topical use and methods for improving animal skin health. The compositions are useful for treating an inflammatory skin condition by the topical application of an emulsion as an ointment, a cream, a foam, or a gel.

The formulation describe the preparation of an analgesic balm which comprises camphor, menthol, thymol, essential oils; e.g., wintergreen oil, eucalyptus oil, turpentine oil & cinnamomun oil; and hard wax in petroleum jelly base. This preparation is excellent in the precutanous absorption of menthol, thymol and provides good result upon use. It is prepared for topical use and effective for stiff joint pain, sciatica, headache and deep seated muscular pain. Its result is much better than othef marketed available drugs for same purpose.